Palisade Bio Inc PALI

Healthcare Biotechnology

Palisade Bio, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal diseases. It is engaged in advancing a PALI-2108 for the treatment of IBD, including UC and CD and are researching PALI-1908. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract. UC primarily affects the colon and the rectum. CD can affect any part of the gastrointestinal tract, from the mouth to the anus. PALI-2108 is a prodrug PDE4 inhibitor that operates through a mechanism within colon tissues, targeting the key enzyme phosphodiesterase-4 (PDE4). This enzyme is pivotal in cAMP hydrolysis, and by inhibiting PDE4, intracellular cAMP levels are elevated. This elevation leads to the downregulation of inflammatory cytokines and a reduction in the expression of cell adhesion molecules. By modulating these processes, PALI-2108 prevents the local infiltration and activation of inflammatory cells in the colon tissues.

NDAQ:PALI - Post by User

Palisade Bio Inc > PALI....pre-market runner

<< Previous

Bullboard Posts

Next >>

Comment by Iseneschalon May 13, 2021 2:57pm

64 Views

Post# 33196249

RE:PALI....pre-market runner

Iseneschal wrote: Ah yes.......PALI.....the old SNCA....after 3 Reverse Splits and the last one was April 28/21 6 : 1 ratio.

SNCA was a train wreck.....PALI might have a shot...just because it's still relatively cheap post RS

GL

Cheers !

Just another typical effing runner that imploded right after burning all the "Retail Day-traders"

Got my money back by scalping it later ...after the big dip then sold the mini rip...

Maddapakkas !!!!!!!!!!

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (Nov. 22, 2024)